Fetal Release of Copeptin in Response to Maternal Oxytocin Administration

Wellmann, Sven; Koslowski, Andrea; Spanaus, Katharina; Zimmermann, Roland; Burkhardt, Tilo

doi:10.1097/aog.0000000000001594

Cited by 20 publications

(20 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This result with copeptin is most likely explained by very recent observations that just a few contractions (most likely acting via transient periods of minor hypoxia on the fetus) are sufficient to trigger detectable AVP/copeptin [24]. Given the cumulative nature of the copeptin levels with a half-life of 30 min [25], the above dependence on labor duration is readily explained.…”

Section: Discussionmentioning

confidence: 85%

Comparison of Umbilical Serum Copeptin Relative to Erythropoietin and S100B as Asphyxia Biomarkers at Birth

Summanen¹,

Seikku²,

Rahkonen³

et al. 2017

Neonatology

View full text Add to dashboard Cite

Background: Birth asphyxia, estimated to account for a million neonatal deaths annually, can cause a wide variety of neurodevelopmental impairments. There is a need to develop new, swift methods to identify those neonates who would benefit from neuroprotective treatments such as hypothermia. Objectives: To examine the utility of cord serum copeptin, a stable byproduct of arginine vasopressin release, as a biomarker of birth asphyxia based on a comparison with 2 biomarkers of hypoxia and brain trauma: erythropoietin and S100B. Methods: The study population consisted of 140 singleton, term neonates: 113 controls and 27 with birth asphyxia (2/3 criteria met: umbilical artery pH <7.10, base excess ≤12 mmol/L, and 5-min Apgar score <7). All deliveries were planned vaginal, but 51 neonates were born by emergency cesarean section. Copeptin, S100B, and erythropoietin levels in umbilical artery samples were measured by immunoassays. Results: Copeptin correlated in the entire study population more strongly with umbilical artery base excess than S100B and erythropoietin, and only copeptin correlated with arterial pH. Furthermore, only copeptin levels were significantly higher in cases of birth asphyxia, and in vaginally born neonates they were found to increase as a function of labor duration. Copeptin was elevated in neonates born via vacuum extraction, whereas erythropoietin levels showed a slight increase after emergency cesarean section. Conclusions: In this study population, S100B and erythropoietin were not valid biomarkers of birth asphyxia. In contrast, our work suggests that copeptin has high potential to become a routinely used biomarker for acute birth asphyxia and neonatal distress.

show abstract

Section: Discussionmentioning

confidence: 85%

Comparison of Umbilical Serum Copeptin Relative to Erythropoietin and S100B as Asphyxia Biomarkers at Birth

Summanen¹,

Seikku²,

Rahkonen³

et al. 2017

Neonatology

View full text Add to dashboard Cite

show abstract

“…Furthermore, in a very recent paper, Wellmann et al . showed that even a few contractions induced by exogenous oxytocin before primary cesarean section are enough to increase the copeptin concentrations in the umbilical cord serum of the neonate, indicating that AVP release is directly linked to transient periods of hypoxia [ 28 ]. Secondly, the time course of AVP/copeptin release, with highest levels measured in umbilical cord serum followed by a progressive decline in serum concentrations, is an advantageous property of an early biomarker, assisting in clinical decisions regarding treatment of asphyxiated neonates already in the first hours after birth.…”

Section: Discussionmentioning

confidence: 99%

Serum copeptin and neuron specific enolase are markers of neonatal distress and long-term neurodevelopmental outcome

et al. 2017

View full text Add to dashboard Cite

The objective of this study was to evaluate the early changes in serial serum levels of copeptin and neuron-specific enolase (NSE) in neonates diagnosed with birth asphyxia, and to determine whether these biomarkers measured in the first 168 hours after birth are predictive of long-term neurodevelopmental outcome. Copeptin and NSE levels were measured from serum samples collected 6, 12, 24, 48, 72, and 168 hours after birth from 75 term neonates diagnosed with hypoxic-ischemic encephalopathy (HIE) and treated with therapeutic hypothermia for 72 hours. In addition, serum copeptin levels after birth were measured from 10 HIE diagnosed neonates, who were randomized to the normothermic arm of the TOBY cohort. All neonates underwent neurodevelopmental assessment using the Bayley Scales of Infant and Toddler Development-II at two years of age. Copeptin levels were highest at 6 hours after birth and steadily decreased, whereas the highest NSE levels were measured at 24 hours after birth. The biomarker levels correlated with blood-gas parameters (base excess, pH and lactate) at 6 and 12 hours after birth. Copeptin and NSE levels in the early postnatal period were significantly higher in neonates with poor outcome compared to those with favorable outcome at two years of age. Furthermore, in the TOBY cohort, copeptin levels were significantly lower in hypothermic compared to normothermic neonates. To conclude, copeptin and NSE measured in the early postnatal period are potential prognostic biomarkers of long-term neurodevelopmental outcome in term neonates diagnosed with HIE and treated with therapeutic hypothermia.

show abstract

“…Very recently, we completed a randomized controlled trial with a truncated oxytocin challenge test 2 h prior to elective cesarean section with subsequent arterial umbilical cord blood sampling at birth. Plasma copeptin levels were found to be threefold higher in the newborn babies of the oxytocin group than in the placebo infants without any evidence of fetal acidosis ( 114 ). Interestingly, only half the women in the oxytocin group noticed the contractions, indicating that the mild subclinical contractions are sufficient to trigger fetal AVP/copeptin release.…”

Section: Labor and Avp And Copeptin Releasementioning

confidence: 96%

Arginine Vasopressin and Copeptin in Perinatology

Evers

Wellmann

2016

Front. Pediatr.

Self Cite

View full text Add to dashboard Cite

Arginine vasopressin (AVP) plays a major role in the homeostasis of fluid balance, vascular tonus, and the regulation of the endocrine stress response. The measurement of AVP levels is difficult due to its short half-life and laborious method of detection. Copeptin is a more stable peptide derived from the same precursor molecule, is released in an equimolar ratio to AVP, and has a very similar response to osmotic, hemodynamic, and stress-related stimuli. In fact, copeptin has been propagated as surrogate marker to indirectly determine circulating AVP concentrations in various conditions. Here, we present an overview of the current knowledge on AVP and copeptin in perinatology with a particular focus on the baby’s transition from placenta to lung breathing. We performed a systematic review of the literature on fetal stress hormone levels, including norepinephrine, cortisol, AVP, and copeptin, in regard to birth stress. Finally, diagnostic and therapeutic options for copeptin measurement and AVP functions are discussed.

show abstract

Fetal Release of Copeptin in Response to Maternal Oxytocin Administration

Abstract: ClinicalTrials.gov, https://clinicaltrials.gov, NCT01962701.

Cited by 20 publications

References 33 publications

Comparison of Umbilical Serum Copeptin Relative to Erythropoietin and S100B as Asphyxia Biomarkers at Birth

Comparison of Umbilical Serum Copeptin Relative to Erythropoietin and S100B as Asphyxia Biomarkers at Birth

Serum copeptin and neuron specific enolase are markers of neonatal distress and long-term neurodevelopmental outcome

Arginine Vasopressin and Copeptin in Perinatology

Contact Info

Product

Resources

About